The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy;El papel de manitol como nefroprotector en pacientes que reciben terapia con cisplatino

Annals of Pharmacotherapy

Volumn 46, Issue 2, 2012, Pages 276-281

  Morgan, Katherine P ^a   Buie, Larry W ^b   Savage, Scott W ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Cisplatin; Mannitol; Nephrotoxicity

Indexed keywords

CISPLATIN; CREATININE; ELECTROLYTE; FLUOROURACIL; FUROSEMIDE; MANNITOL; PACLITAXEL; SODIUM CHLORIDE;

ADVANCED CANCER; BOLUS INJECTION; CREATININE CLEARANCE; DIURESIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE GENITAL TRACT TUMOR; HUMAN; HYDRATION; KIDNEY FUNCTION; KIDNEY TUBULE; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; UREA NITROGEN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; KIDNEY DISEASES; MANNITOL; PROTECTIVE AGENTS;

EID: 84857017567     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q333     Document Type: Review

References (19)

1. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984;100:704-13.
2. De Conti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res J 1973;33:1310-5.
3. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334:115-24.
4. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007.
5. Hartman JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866-9.
6. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977;39:1362-71.
7. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 1988;44:164-72.
8. Higby DJ, Wallace HJ, Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer 1974;33:1219-25.
9. Frick GA, Ballentine R, Driever CW, Kramer WG. Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis. Cancer Treat Rep 1979;63:13-6.
10. Visweswaren P, Massin E, Dubose TD. Mannitol-induced acute renal failure. J Am Soc Nephrol 1997;8:1028-33.
11. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride; amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39:1372-81.
12. Chary KK, Higby DJ, Henderson ES, Swinerton KD. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treat Rep 1977;61:367-70.
13. Groth S, Nielsen H, Sorenson JB, Christensen AB, Pedersen AG, Rorth M. Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 1986;17:191-6.
14. Legha SS, Dimery IW. High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 1985;3:1373-8.
15. Ostrow S, Egorin MJ, Hahn D, et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 1981;65:73-8.
16. Al-Sarraf M, Fletcher W, Oishisi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 1982; 66:31-5.
17. Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan E. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003;52:13-8.
18. Leu L, Baribeault D. A comparison of the rates of cisplatin (cDDP)-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract 2010;16:167-71.
19. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art recommendations from the European Society of Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008;61:903-9.